Announcements & Media Coverage

Hemogenyx Pharmaceuticals plc (“Hemogenyx” or the “Company”)   Hemogenyx’s CAR-T Cells are Effective Against AML in vivo   Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments of blood diseases, is pleased to announce the following update on its activities. As previously announced, Hemogenyx’s CDX product has the potential to treat...